Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Tarja Ruotsalainen"'
Autor:
Tuija Poussa, Hilpi Rautelin, Tarja Ruotsalainen, Leena Maija Soveri, Pia Österlund, Petri Bono
Publikováno v:
Oncology Letters
5-Fluorouracil (5-FU)-based chemotherapy is the mainstay of adjuvant treatment for colorectal cancer (CRC). Few studies have explored Helicobacter pylori (H. pylori)-associated gastrointestinal symptoms in the diagnosis of CRC, and the association be
Autor:
Heikki Joensuu, Maija Saxelin, M. Kouri, Tarja Ruotsalainen, A Ollus, Inkeri Elomaa, Pia Österlund, Päivi Valta, Riitta Korpela
Publikováno v:
British Journal of Cancer
5-Fluorouracil (5-FU)-based chemotherapy is frequently associated with diarrhoea. We compared two 5-FU-based regimens and the effect of Lactobacillus and fibre supplementation on treatment tolerability. Patients diagnosed with colorectal cancer (n=15
Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer
Autor:
Tarja Ruotsalainen, Inkeri Elomaa, Riitta Korpela, Pia Österlund, Katri Peuhkuri, Heikki Joensuu, Minna Ikonen, Anneli Ollus
Publikováno v:
Clinical Gastroenterology and Hepatology. 2:696-703
Bowel mucosal injury associated with 5-fluorouracil (5-FU) treatment might result in secondary lactose intolerance. The frequency and clinical significance of 5-FU-related hypolactasia are unknown.One hundred fifty patients randomly assigned to recei
Publikováno v:
Lung Cancer. 41:171-177
Syndecan-1 is a multifunctional transmembrane heparan sulphate proteoglycan (HSPG) that is present on a variety of cell types. The extracellular syndecan domains can be shed from the cell surface in a highly regulated process called ectodomain sheddi
Autor:
O.-P. Isokangas, Markku Pekonen, Seppo Sarna, M. Mäntylä, Tarja Ruotsalainen, Maija Halme, Seppo Pyrhönen, Karin Mattson, Heikki Joensuu
Publikováno v:
Anti-Cancer Drugs. 11:101-108
This randomized phase II multi-center study was designed to determine the time to progression, duration of response and the feasibility of an intensified maintenance regime consisting of a combination of interferon (IFN)-alpha and retinoic acid after
Autor:
Heikki Joensuu, M. Mäntylä, Klaus Tamminen, Paula Maasilta, Janusz Szopinski, Seppo Sarna, Tarja Ruotsalainen, Antti Jekunen, Maija Halme, Mikael Kajanti, Kari Cantell, Seppo Pyrhönen, Karin Mattson, A. Niiranen, Henrik Riska
Publikováno v:
University of Helsinki
Patients with any stage of small cell lung cancer were given low-dose interferon-alpha (IFN-alpha) from the first day of treatment as long as possible irrespective of changes in treatment dictated by disease progression. All patients received 6 cycle
Autor:
Tarja Ruotsalainen, Paula Maasilta, Markku Pekonen, Anneli Piilonen, Maija Halme, Eero Taskinen, Mikko Hallman, Karin Mattson
Publikováno v:
Lung Cancer. 23:39-52
The aim of this study was to determine whether either natural or recombinant interferon (IFN)-alpha can improve the response to radiotherapy (RT) in patients with small cell lung cancer (SCLC), and to assess the role of IFN in radiation-induced lung
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 11(11)
Basic fibroblast growth factor (bFGF) is a secreted multifunctional cytokine and a potent stimulator of angiogenesis. We measured bFGF concentrations from serum samples taken from 103 patients with small cell lung cancer at the time of diagnosis. Ser
Autor:
Karin Mattson, Tarja Ruotsalainen
Publikováno v:
Journal of interferoncytokine research : the official journal of the International Society for Interferon and Cytokine Research. 22(2)
Chemotherapy became the primary treatment for small cell lung cancer (SCLC) in the early 1970s. The standard drug combinations were first vincristine, adriamycin, and cyclophosphamide (VAC) and then, from the early 1980s, etoposide-platinum combinati
Publikováno v:
International journal of cancer. 79(2)
Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and vascular permeability. Increased serum VEGF concentrations (S-VEGF) have been found in patients with various types of human cancer, including cancer of the lung.